What is the purpose of the Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)?
The purpose of the Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) was to investigate the effectiveness of using alteplase to treat acute ischaemic stroke. The study was conducted by the Second European-Australasian Acute Stroke Study Investigators and published in the Lancet in 1998. The results of the study showed that alteplase was beneficial in reducing long-term disability in patients with acute ischaemic stroke.